首页 | 本学科首页   官方微博 | 高级检索  
检索        


Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B‐cell lymphomas
Authors:Marta Scandurra  Davide Rossi  Clara Deambrogi  Paola MV Rancoita  Ekaterina Chigrinova  Michael Mian  Michaela Cerri  Silvia Rasi  Elisa Sozzi  Francesco Forconi  Maurilio Ponzoni  Santiago M Moreno  Miguel A Piris  Giorgio Inghirami  Emanuele Zucca  Valter Gattei  Andrea Rinaldi  Ivo Kwee  Gianluca Gaidano  Francesco Bertoni
Institution:1. Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland;2. Division of Hematology, Department of Clinical and Experimental Medicine & BRMA, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;3. Istituto Dalle Molle di Studi sull'Intelligenza Artificiale, Manno, Switzerland;4. Divisione di Ematologia, Azienda Ospedaliera S. Maurizio, Bolzano/Bozen, Italy;5. Ematologia e Trapianti, Università di Siena and AOUS, Siena, Italy;6. San Raffaele H Scientific Institute, Pathology Unit and Unit of Lymphoid Malignancies, Milan, Italy;7. Programa de Patologia Molecular, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain;8. Department of Pathology and Center for Experimental Research and Medical Studies (CeRMS), University of Turin, Turin, Italy;9. Clinical and Experimental Onco‐Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy
Abstract:Richter's syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma and is mostly represented by diffuse large B‐cell lymphoma (DLBCL), with a post‐germinal centre (GC) phenotype, clonally related to the pre‐existing CLL. RS has a very poor prognosis and its pathogenetic mechanisms are poorly understood. In order to gain additional hints in RS pathogenesis, we performed a genome‐wide DNA profiling study of 13 RS phases and eight matched CLL phases using the Affymetrix Human Mapping 250K NspI SNP arrays. Individual genomic profiles were heterogeneous, with no individual lesions occurring in more than half of the cases. However, several observations suggest that MYC pathway might be involved in RS. The 13q13.3‐qter region containing MIRHG1 (MIR‐17‐92), a cluster of microRNA interacting with c‐MYC, was acquired at the time of transformation. The 13q gain was coupled with the gain of c‐MYC and loss of TP53. Translocation of c‐MYC was acquired at transformation in a fraction of cases and this event appeared mutually exclusive with gain of MIRHG1. MYCN, a c‐MYC homologue, was also recurrently gained. By comparing RS with 48 de novo DLBCL, RS presented a significantly lower prevalence of deletions affecting the PRDM1 and TNFAIP3, genes on 6q, known to be associated with a post‐GC phenotype. In conclusion, the genomic profile of RS seems to differ from what observed in de novo DLBCL and in other transformed DLBCL. Genomic lesions occurring in RS are heterogeneous suggesting the existence of different RS subsets, possibly due to different transforming mechanisms. A deregulation of MYC pathway might represent one of the main transformation events in the pathogenesis of a subset of RS clonally related to the previous CLL. Copyright © 2009 John Wiley & Sons, Ltd.
Keywords:lymphoma  MYC  chronic lymphocytic leukaemia  13q  8q  Affymetrix  MIRHG1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号